OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 200,000 Shares

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost purchased 200,000 shares of the company's stock in a transaction dated Monday, March 17th. The stock was purchased at an average price of $1.74 per share, for a total transaction of $348,000.00. Following the transaction, the chief executive officer now directly owns 213,501,448 shares in the company, valued at approximately $371,492,519.52. This trade represents a 0.09 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, February 28th, Phillip Md Et Al Frost bought 67,434 shares of OPKO Health stock. The shares were bought at an average price of $1.71 per share, for a total transaction of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock. The shares were acquired at an average price of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.47 per share, for a total transaction of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.48 per share, with a total value of $740,000.00.

OPKO Health Price Performance

OPK traded down $0.03 on Friday, reaching $1.80. The company had a trading volume of 2,568,213 shares, compared to its average volume of 4,476,785. OPKO Health, Inc. has a 52-week low of $0.89 and a 52-week high of $2.04. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The business has a 50 day simple moving average of $1.65 and a 200 day simple moving average of $1.57. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -9.45 and a beta of 1.70.

Remove Ads

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.09. The firm had revenue of $183.60 million for the quarter, compared to analysts' expectations of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, sell-side analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current year.

Institutional Investors Weigh In On OPKO Health

Several large investors have recently bought and sold shares of OPK. Rubric Capital Management LP grew its stake in shares of OPKO Health by 9.6% during the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company's stock valued at $72,573,000 after acquiring an additional 4,284,336 shares during the period. Barclays PLC grew its stake in OPKO Health by 154.5% in the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company's stock valued at $810,000 after purchasing an additional 329,870 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in OPKO Health by 736.7% in the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company's stock worth $368,000 after acquiring an additional 217,450 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of OPKO Health during the third quarter worth about $190,000. Finally, FMR LLC raised its position in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 11,089 shares in the last quarter. 64.63% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

OPK has been the subject of several research reports. HC Wainwright restated a "buy" rating and set a $3.00 price target on shares of OPKO Health in a research report on Wednesday. Barrington Research reissued an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a report on Wednesday, March 12th. Finally, StockNews.com raised shares of OPKO Health from a "sell" rating to a "hold" rating in a report on Monday, March 3rd.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.